Article in Science immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Alejandro Marin-LopezSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0003-2840-1722
John D HuckDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Allen T EsterlyDepartment of Microbiology and Immunology, State University of New York, Upstate Medical University, Syracuse, NY, USA.ORCID 0000-0003-1132-6797
Veronica AzcutiaDepartment of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA.ORCID 0000-0003-2160-5175
Connor RosenDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0003-2442-3676
Rolando Garcia-MilianBioinformatics Support Program, Cushing/Whitney Medical Library, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0003-1557-566X
Esen SefikDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-6807-3498
Gemma Vidal-PedrolaSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
Hamidah RaduwanSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-4939-7809
Tse-Yu ChenSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-8281-909X
Gunjan AroraSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0003-0575-6205
Stephanie HaleneSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-2737-9810
Albert C ShawSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0003-4970-7640
Noah W PalmDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0001-7262-9455
Richard A FlavellDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0003-4461-0778
Charles A ParkosDepartment of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA.ORCID 0000-0002-2490-7657
Saravanan ThangamaniDepartment of Microbiology and Immunology, State University of New York, Upstate Medical University, Syracuse, NY, USA.ORCID 0000-0002-4269-5993
Aaron M RingDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0003-3699-2446
Erol FikrigSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-5884-6047
Funding
Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI YASUKO IWAKIRI · 1986 to 2026
$31.1M
Intestinal Inflammation: Signaling proteins and the rate of PMN transmigrationR01DK079392 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PARKOS, CHARLES A · 2007 to 2025
$7.2M
A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1R42AI142846 · NIAID · L2 DIAGNOSTICS, LLC · PI FIKRIG, EROL, MARIN LOPEZ, ALEJANDRO · 2022 to 2024
$2.9M
Vaccination against Zika virus infection using mosquito NeSt1 proteinR41AI152904 · NIAID · L2 DIAGNOSTICS, LLC · PI LEDIZET, MICHEL · 2020 to 2021
$593k
Howard Hughes Medical InstituteNIAID NIH HHS R41 AI152904NIAID NIH HHS R42 AI142846NIDDK NIH HHS P30 DK034989NIDDK NIH HHS R01 DK079392
6 · The paper itself
Abstract
The
Indexed as
AedesSkinZika VirusAnimalsCD47 AntigenFemaleHumansInsect ProteinsMosquito VectorsSalivary Proteins and PeptidesZika Virus InfectionCD47 AntigenCD47 protein, humanInsect ProteinsSalivary Proteins and Peptides
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The human CD47 checkpoint is targeted by an immunosuppressive · full record | OpenQuestion